Does restraining nitric oxide biosynthesis rescue from toxins-induced parkinsonism and sporadic parkinson's disease?

Molecular Neurobiology

Volumn 49, Issue 1, 2014, Pages 262-275

  Gupta, Satya Prakash ^a   Yadav, Sharawan ^a   Singhal, Naveen Kumar ^a   Tiwari, Manindra Nath ^a   Mishra, Sarad Kumar ^b   Singh, Mahendra Pratap ^a,c  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b D D U GORAKHPUR UNIVERSITY   (India)

^c ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

Author keywords

Nitric oxide; Nitric oxide synthase; Nitric oxide synthase inhibitors; Parkinson's disease; Rodent models

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMPHETAMINE; CYCLIC GMP DEPENDENT PROTEIN KINASE; GUANYLATE CYCLASE; LIPOPOLYSACCHARIDE; MANEB; METHAMPHETAMINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; PARAQUAT; PEROXYNITRITE; REACTIVE NITROGEN SPECIES; RESERPINE; ROTENONE; TOXIN;

APOPTOSIS; BIOSYNTHESIS; CEREBROSPINAL FLUID; DNA DAMAGE; GENETIC RISK; HUMAN; IN VITRO STUDY; MICROGLIA; MITOCHONDRION; NIGRONEOSTRIATAL SYSTEM; NITROSATIVE STRESS; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; HUMANS; METHAMPHETAMINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PARKINSONIAN DISORDERS; REACTIVE NITROGEN SPECIES; ROTENONE;

EID: 84894369187     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8517-4     Document Type: Review

References (129)

1. Singh MP, Patel S, Dikshit M, Gupta YK (2006) Contribution of genomics and proteomics in understanding the role of modifying factors in Parkinson's disease. Indian J Biochem Biophys 43:69-81
2. Yadav S, Dixit A, Agrawal S, Singh A, Srivastava G, Singh AK, Srivastava PK, Prakash O, Singh MP (2012) Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis. Mol Neurobiol 46:495-512
3. Dixit A, Srivastava G, Verma D, Mishra M, Singh PK, Prakash O, Singh MP (2013) Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease. Biochim Biophys Acta 1832:1227-1240
4. Moncada S, Higgs EA (2006) The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 147:S193-S201
5. Jachymova M, Masters BS, Horky K, Zima T, Martasek P (2006) Nitric oxide synthase, typical flavohemoproteins and their complicated enzymology. Cas Lek Cesk 145:526-531
6. Zhou L, Zhu DY (2009) Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 20:223-230
7. Culotta E, Koshland DE Jr (1992) NO news is good news. (nitric oxide; includes information about other significant advances & discoveries of 1992) (Molecule of the Year). Science 258(5090):1862-1864
8. Kavya R, Saluja R, Singh S, Dikshit M (2006) Nitric oxide synthase regulation and diversity: implications in Parkinson's disease. Nitric Oxide 15:280-294
9. Chinje EC, Stratford IJ (1997) Role of nitric oxide in growth of solid tumours: a balancing act. Essays Biochem 32:61-72
10. Liu Q, Gross SS (1996) Binding sites of nitric oxide synthases. Methods Enzymol 268:311-324
11. Panda K, Rosenfeld RJ, Ghosh S, Meade AL, Getzoff ED, Stuehr DJ (2002) Distinct dimer interaction and regulation in nitric-oxide synthase types I, II, and III. J Biol Chem 277:31020-31030
12. Ponting CP, Phillips C (1995) DHR domains in syntrophins, neuronal NO synthases and other intracellular proteins. Trends Biochem Sci 20:102-103
13. Aquilano K, Baldelli S, Rotilio G, Ciriolo MR (2008) Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem Res 33:2416-2426
14. Knowles RG, Moncada S (1994) Nitric oxide synthases in mammals. Biochem J 298:249-258
15. Duan W, Zhou J, Li W, Zhou T, Chen Q, Yang F, Wei T (2013) Plasma membrane calcium ATPase 4b inhibits nitric oxide generation through calcium-induced dynamic interaction with neuronal nitric oxide synthase. Protein Cell 4:286-298
16. Gupta SP, Patel S, Yadav S, Singh AK, Singh S, Singh MP (2010) Involvement of nitric oxide in maneb- and paraquat-induced Parkinson's disease phenotype in mouse: is there any link with lipid peroxidation? Neurochem Res 35:1206-1213
17. Singhal NK, Srivastava G, Patel DK, Jain SK, Singh MP (2011) Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson's disease phenotype in the mouse. J Pineal Res 50:97-109
18. Kavya R, Dikshit M (2005) Role of nitric oxide/nitric oxide synthase in Parkinson's disease. Ann Neurosci 12:1-5
19. Nelson EJ, Connolly J, McArthur P (2003) Nitric oxide and S-nitrosylation: excitotoxic and cell signaling mechanism. Biol Cell 95:3-8
20. Madhusoodanan KS, Murad F (2007) NO-cGMP signaling and regenerative medicine involving stem cells. Neurochem Res 32:681-694
21. Hall ED, Wang JA, Miller DM (2012) Relationship of nitric oxide synthase induction to peroxynitrite-mediated oxidative damage during the first week after experimental traumatic brain injury. Exp Neurol 238:176-182
22. Chalimoniuk M, Langfort J, Lukacova N, Marsala J (2004) Upregulation of guanylyl cyclase expression and activity in striatum of MPTP-induced parkinsonism in mice. Biochem Biophys Res Commun 324:118-126
23. Kanao T, Sawada T, Davies SA, Ichinose H, Hasegawa K, Takahashi R, Hattori N, Imai Y (2012) The nitric oxide-cyclic GMP pathway regulates FoxO and alters dopaminergic neuron survival in Drosophila. PLoS One 7(2):e30958
24. Cooke RM, Mistry R, Challiss RA, Straub VA (2013) Nitric oxide synthesis and cGMP production is important for neurite growth and synapse remodeling after axotomy. J Neurosci 33:5626-5637
25. Chalimoniuk M, Stolecka A, Ziemińska E, Stepień A, Langfort J, Strosznajder JB (2009) Involvement of multiple protein kinases in cPLA2 phosphorylation, arachidonic acid release, and cell death in in vivo and in vitro models of 1-methyl-4-phenylpyridinium-induced parkinsonism - the possible key role of PKG. J Neurochem 110:307-317
26. Moncada S, Erusalimsky JD (2002) Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nat Rev Mol Cell Biol 3:214-220
27. Singh S, Zhuo M, Gorgun M, Englander EW (2013) Overexpressed neuroglobin raises threshold for nitric oxide-induced impairment of mitochondrial respiratory activities and stress signaling in primary cortical neurons. Nitric Oxide 32:21-28
28. Erusalimsky JD, Moncada S (2007) Nitric oxide and mitochondrial signaling: from physiology to pathophysiology. Arterioscler Thromb Vasc Biol 27:2524-2531
29. Hwang O (2013) Role of oxidative stress in Parkinson's disease. Exp Neurobiol 22:11-17
30. Akhtar MW, Sunico CR, Nakamura T, Lipton SA (2012) Redox regulation of protein function via cysteine S-nitrosylation and its relevance to neurodegenerative diseases. Int J Cell Biol 2012:463756
31. Shergill JK, Cammack R, Cooper CE, Cooper JM, Mann VM, Schapira AH (1996) Detection of nitrosyl complexes in human substantia nigra, in relation to Parkinson's disease. Biochem Biophys Res Commun 12:298-305
32. Zhang W, Phillips K, Wielgus AR, Liu J, Albertini A, Zucca FA, Faust R, Qian SY, Miller DS, Chignell CF, Wilson B, Jackson-Lewis V, Przedborski S, Joset D, Loike J, Hong JS, Sulzer D, Zecca L (2011) Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res 19:63-72
33. Ghosh A, Kanthasamy A, Joseph J, Anantharam V, Srivastava P, Dranka BP, Kalyanaraman B, Kanthasamy AG (2012) Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease. J Neuroinflammation 9:241
34. Sung YH, Kim SC, Hong HP, Park CY, Shin MS, Kim CJ, Seo JH, Kim DY, Kim DJ, Cho HJ (2012) Treadmill exercise ameliorates dopaminergic neuronal loss through suppressing microglial activation in Parkinson's disease mice. Life Sci 91:1309-1316
35. Matsui T, Motoki Y, Yoshida Y (2013) Hypothermia reduces toll-like receptor 3-activated microglial interferon-β and nitric oxide production. Mediat Inflamm 2013:436263
36. Colombo E, Cordiglieri C, Melli G, Newcombe J, Krumbholz M, Parada LF, Medico E, Hohlfeld R, Meinl E, Farina C (2012) Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration. J Exp Med 209:521-535
37. Kim SU, Park YH, Min JS, Sun HN, Han YH, Hua JM, Lee TH, Lee SR, Chang KT, Kang SW, Kim JM, Yu DY, Lee SH, Lee DS (2013) Peroxiredoxin I is a ROS/p38 MAPK-dependent inducible antioxidant that regulates NF-κB-mediated iNOS induction and microglial activation. J Neuroimmunol 259:26-36
38. Hoang T, Choi DK, Nagai M, Wu DC, Nagata T, Prou D, Wilson GL, Vila M, Jackson-Lewis V, Dawson VL, Dawson TM, Chesselet MF, Przedborski S (2009) Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radic Biol Med 47:1049-1056
39. Boyd CS, Cadenas E (2002) Nitric oxide and cell signaling pathways in mitochondrial-dependent apoptosis. Biol Chem 383:411-423
40. Perier C, Tieu K, Guegan C, Caspersen C, Jakson-Lewis V, Carelli V, Martinuzzi A, Hirano M, Przedborski S, Vila M (2005) Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A 102:19126-19131
41. Guo S, Yan J, Yang T, Yang X, Bezard E, Zhao B (2007) Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway. Biol Psychiatry 62:1353-1362
42. Hancock DB, Martin ER, Vance JM, Scott WK (2008) Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease. Neurogenetics 9:249-262
43. Montesanto A, Crocco P, Tallaro F, Pisani F, Mazzei B, Mari V, Corsonello A, Lattanzio F, Passarino G, Rose G (2013) Common polymorphisms in nitric oxide synthase (NOS) genes influence quality of aging and longevity in humans. Biogerontology 14:177-186
44. Schulte C, Sharma M, Mueller JC, Lichtner P, Prestel J, Berg D, Gasser T (2006) Comprehensive association analysis of the NOS2A gene with Parkinson disease. Neurology 67:2080-2082
45. Huerta C, Sánchez-Ferrero E, Coto E, Blázquez M, Ribacoba R, Guisasola LM, Salvador C, Alvarez V (2007) No association between Parkinson's disease and three polymorphisms in the eNOS, nNOS, and iNOS genes. Neurosci Lett 413:202-205
46. Rife T, Rasoul B, Pullen N, Mitchell D, Grathwol K, Kurth J (2009) The effect of a promoter polymorphism on the transcription of nitric oxide synthase 1 and its relevance to Parkinson's disease. J Neurosci Res 87:2319-2325
47. Lo HS, Hogan EL, Soong BW (2002) 5′-Flanking region polymorphism of the neuronal nitric oxide synthase gene with Parkinson's disease in Taiwan. J Neurol Sci 194:11-13
48. Hancock DB, Martin ER, Fujiwara K, Stacy MA, Scott BL, Stajich JM, Jewett R, Li YJ, Hauser MA, Vance JM, Scott WK (2006) NOS2A and the modulating effect of cigarette smoking in Parkinson's disease. Ann Neurol 60:366-373
49. Levecque C, Elbaz A, Clavel J, Richard F, Vidal JS, Amouyel P, Tzourio C, Alpérovitch A, Chartier-Harlin MC (2003) Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. Hum Mol Genet 12:79-86
50. Sinha A, Srivastava N, Singh S, Singh AK, Bhushan S, Shukla R, Singh MP (2009) Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson's disease patients: a proteomic approach. Clin Chim Acta 400:14-20
51. Beyer K (2007) Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane. Cell Biochem Biophys 47:285-299
52. Reif DW, Simmons RD (1990) Nitric oxide mediates iron release from ferritin. Arch Biochem Biophys 283:537-541
53. Luong KV, Nguyen LT (2012) Thiamine and Parkinson's disease. J Neurol Sci 316:1-8
54. Gu Z, Nakamura T, Lipton SA (2010) Redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Mol Neurobiol 41:55-72
55. Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, Dawson VL, Dawson TM (2004) S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304:1328-1331
56. Yao D, Gu Z, Nakamura T, Shi ZQ, Ma Y, Gaston B, Palmer LA, Rockenstein EM, Zhang Z, Masliah E, Uehara T, Lipton SA (2004) Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci U S A 101:10810-10814
57. Fang J, Nakamura T, Cho DH, Gu Z, Lipton SA (2007) S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease. Proc Natl Acad Sci U S A 104:18742-1847
58. Betarbet R, Sherer TB, Greenamyre JT (2002) Animal models of Parkinson's disease. Bioessays 24:308-318
59. Choi HJ, Lee SY, Cho Y, Hwang O (2004) JNK activation by tetrahydrobiopterin: implication for Parkinson's disease. J Neurosci Res 75:715-721
60. Joniec I, Ciesielska A, Kurkowska-Jastrzebska I, Przybylkowski A, Czlonkowska A, Czlonkowski A (2009) Age and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res 1261:7-19
61. Nakamura T, Lipton SA (2011) S-nitrosylation of critical protein thiols mediates protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Antioxid Redox Signal 14:1479-1492
62. Hara MR, Thomas B, Cascio MB, Bae BI, Hester LD, Dawson VL, Dawson TM, Sawa A, Snyder SH (2006) Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci U S A 103:3887-3889
63. Kim HG, Ju MS, Ha SK, Lee H, Lee H, Kim SY, Oh MS (2012) Acacetin protects dopaminergic cells against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neuroinflammation in vitro and in vivo. Biol Pharm Bull 35:1287-1294
64. Roy A, Ghosh A, Jana A, Liu X, Brahmachari S, Gendelman HE, Pahan K (2012) Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease. PLoS One 7:e38113
65. Di Matteo V, Pierucci M, Benigno A, Crescimanno G, Esposito E, Di Giovanni G (2009) Involvement of nitric oxide in nigrostriatal dopaminergic system degeneration: a neurochemical study. Ann N Y Acad Sci 1155:309-315
66. Yuste JE, Echeverry MB, Ros-Bernal F, Gomez A, Ros CM, Campuzano CM, Fernandez-Villalba E, Herrero MT (2012) 7-Nitroindazole down-regulates dopamine/DARPP-32 signaling in neostriatal neurons in a rat model of Parkinson's disease. Neuropharmacology 63:1258-1267
67. Singh S, Kumar S, Dikshit M (2010) Involvement of the mitochondrial apoptotic pathway and nitric oxide synthase in dopaminergic neuronal death induced by 6-hydroxydopamine and lipopolysaccharide. Redox Rep 15:115-122
68. Singh S, Das T, Ravindran A, Chaturvedi RK, Shukla Y, Agarwal AK, Dikshit M (2005) Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson's disease. Redox Rep 10:103-109
69. Li M, Dai FR, Du XP, Yang QD, Chen Y (2012) Neuroprotection by silencing iNOS expression in a 6-OHDA model of Parkinson's disease. J Mol Neurosci 48:225-233
70. Broom L, Marinova-Mutafchieva L, Sadeghian M, Davis JB, Medhurst AD, Dexter DT (2011) Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease. Free Radic Biol Med 50:633-640
71. Miller RL, James-Kracke M, Sun GY, Sun AY (2009) Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 34:55-65
72. Gomez C, Bandez MJ, Navarro A (2007) Pesticides and impairment of mitochondrial function in relation with the parkinsonian syndrome. Front Biosci 12:1079-1093
73. Xiong N, Long X, Xiong J, Jia M, Chen C, Huang J, Ghoorah D, Kong X, Lin Z, Wang T (2012) Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models. Crit Rev Toxicol 42:613-632
74. Abdin AA, Sarhan NI (2011) Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and l-dopa toxicity. Neurosci Res 71:387-395
75. Tada-Oikawa S, Hiraku Y, Kawanishi M, Kawanishi S (2003) Mechanism for generation of hydrogen peroxide and change of mitochondrial membrane potential during rotenone-induced apoptosis. Life Sci 73:3277-3288
76. He Y, Imam SZ, Dong Z, Jankovic J, Ali SF, Appel SH, Le W (2003) Role of nitric oxide in rotenone-induced nigro-striatal injury. J Neurochem 86:1338-1345
77. Bashkatova V, Alam M, Vanin A, Schmidt WJ (2004) Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain. Exp Neurol 186:235-241
78. Pal R, Miranda M, Narayan M (2011) Nitrosative stress-induced Parkinsonian Lewy-like aggregates prevented through polyphenolic phytochemical analog intervention. Biochem Biophys Res Commun 404:324-329
79. Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT (2009) A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis 34:279-290
80. Hu LF, Lu M, Tiong CX, Dawe GS, Hu G, Bian JS (2010) Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models. Aging Cell 9:135-146
81. Verma R, Nehru B (2009) Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease. Neurochem Int 55:369-375
82. Bi J, Jiang B, Hao S, Zhang A, Dong Y, Jiang T, An L (2009) Catalpol attenuates nitric oxide increase via ERK signaling pathways induced by rotenone in mesencephalic neurons. Neurochem Int 54:264-270
83. Yadav S, Gupta SP, Srivastava G, Srivastava PK, Singh MP (2012) Role of secondary mediators in caffeine-mediated neuroprotection in maneb- and paraquat-induced Parkinson's disease phenotype in the mouse. Neurochem Res 37:875-884
84. Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B (2009) Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 169:919-926
85. Mangano EN, Litteljohn D, So R, Nelson E, Peters S, Bethune C, Bobyn J, Hayley S (2012) Interferon-γ plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways. Neurobiol Aging 33:1411-1426
86. Wang C, Ko HS, Thomas B, Tsang F, Chew KC, Tay SP, Ho MW, Lim TM, Soong TW, Pletnikova O, Troncoso J, Dawson VL, Dawson TM, Lim KL (2005) Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum Mol Genet 14:3885-3897
87. Shimizu K, Matsubara K, Ohtaki K, Shiono H (2003) Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture. Neurosci Res 46:523-532
88. Shimizu K, Matsubara K, Ohtaki K, Fujimaru S, Saito O, Shiono H (2003) Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats. Brain Res 976:243-252
89. Ahmad I, Kumar A, Shukla S, Prasad Pandey H, Singh C (2008) The involvement of nitric oxide in maneb- and paraquat-induced oxidative stress in rat polymorphonuclear leukocytes. Free Radic Res 42:849-862
90. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20:6309-6316
91. Lee YY, Park JS, Jung JS, Kim DH, Kim HS (2013) Anti-inflammatory effect of ginsenoside Rg5 in lipopolysaccharide-stimulated BV2 microglial cells. Int J Mol Sci 14:9820-9833
92. Arimoto T, Bing G (2003) Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol Dis 12:35-45
93. Di Girolamo G, Farina M, Riberio ML, Ogando D, Aisemberg J, De los Santos AR, Martí ML, Franchi AM (2003) Effects of cyclooxygenase inhibitor pretreatment on nitric oxide production, nNOS and iNOS expression in rat cerebellum. Br J Pharmacol 139:1164-1170
94. Choi DY, Liu M, Hunter RL, Cass WA, Pandya JD, Sullivan PG, Shin EJ, Kim HC, Gash DM, Bing G (2009) Striatal neuroinflammation promotes parkinsonism in rats. PLoS One 4:e5482
95. Tieu K (2011) A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med 1:a009316
96. Pubill D, Chipana C, Camins A, Pallàs M, Camarasa J, Escubedo E (2005) Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol Appl Pharmacol 204:57-68
97. Rajakumar B, Flumerfelt BA, Hrycyshyn AW, Rajakumar N (2007) Nitric oxide-containing neurons in long-term grafts in a rat model of Parkinson's disease. Cell Transplant 16:449-459
98. Ali SF, Itzhak Y (1998) Effects of 7-nitroindazole, an NOS inhibitor on methamphetamine-induced dopaminergic and serotonergic neurotoxicity in mice. Ann N Y Acad Sci 844:122-130
99. Salum C, Issy AC, Brandão ML, Guimarães FS, Bel EA (2011) Nitric oxide modulates dopaminergic regulation of prepulse inhibition in the basolateral amygdala. J Psychopharmacol 25:1639-1648
100. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415-455
101. Bilska A, Dubiel M, Sokołowska-Jezewicz M, Lorenc-Koci E, Włodek L (2007) Alpha-lipoic acid differently affects the reserpine-induced oxidative stress in the striatum and prefrontal cortex of rat brain. Neuroscience 146:1758-1771
102. Tadaiesky MT, Andreatini R, Vital MA (2006) Different effects of 7-nitroindazole in reserpine-induced hypolocomotion in two strains of mice. Eur J Pharmacol 535:199-207
103. Chalimoniuk M, Lukacova N, Marsala J, Langfort J (2006) Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience 141:1033-1046
104. Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R, Matthews RT, Beal MF (1996) Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 2:1017-1021
105. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5(12):1403-1409
106. Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB (2000) Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 74(5):2213-2216
107. Tsang AH, Lee YI, Ko HS, Savitt JM, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM, Chung KK (2009) S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. Proc Natl Acad Sci U S A 106:4900-4905
108. Stone DK, Kiyota T, Mosley RL, Gendelman HE (2012) A model of nitric oxide induced α-synuclein misfolding in Parkinson's disease. Neurosci Lett 523:167-173
109. Rojanathammanee L, Murphy EJ, Combs CK (2011) Expression of mutant alpha-synuclein modulates microglial phenotype in vitro. J Neuroinflammation 8:44
110. Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS (2011) Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect 119:807-814
111. Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL (2008) Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease? Neuroscience 153:733-750
112. Manzoni C (2012) LRRK2 and autophagy: a common pathway for disease. Biochem Soc Trans 40:1147-1151
113. Gillardon F, Schmid R, Draheim H (2012) Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 208:41-48
114. Cherra SJ 3rd, Steer E, Gusdon AM, Kiselyov K, Chu CT (2013) Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons. Am J Pathol 182:474-484
115. Hoepken HH, Gispert S, Morales B, Wingerter O, Del Turco D, Mülsch A, Nussbaum RL, Müller K, Dröse S, Brandt U, Deller T, Wirth B, Kudin AP, Kunz WS, Auburger G (2007) Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol Dis 25:401-411
116. Brzozowski MJ, Alcantara SL, Iravani MM, Rose S, Jenner P (2011) The effect of nNOS inhibitors on toxin-induced cell death in dopaminergic cell lines depends on the extent of enzyme expression. Brain Res 1404:21-30
117. Zorzi G, Thony B, Blau N (2002) Reduced nitric oxide metabolites in CSF of patients with tetrahydrobiopterin deficiency. J Neurochem 80:362-644
118. Gomes MZ, Raisman-Vozari R, Del Bel EA (2008) A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway. Brain Res 1203:160-169
119. Shi C, Zhang YX, Zhang ZF (2009) Effect of phosphorylated-ERK1/2 on inducible nitric oxide synthase expression in the substantia nigra of mice with MPTP-induced Parkinson disease. Nan Fang Yi Ke Da Xue Xue Bao 29:60-63
120. Del-Bel E, Padovan-Neto FE, Raisman-Vozari R, Lazzarini M (2011) Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment. Curr Pharm Des 17:471-488
121. Padovan-Neto FE, Ferreira NR, Tavares D, de Aguiar D, Silva CA, Raisman-Vozari R, Del Bel E (2013) Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/DeltaFosB expression. Neurosci Lett 541:126-131
122. Takuma K, Tanaka T, Takahashi T, Hiramatsu N, Ota Y, Ago Y, Matsuda T (2012) Neuronal nitric oxide synthase inhibition attenuates the development of l-DOPA-induced dyskinesia in hemi-parkinsonian rats. Eur J Pharmacol 683:166-173
123. Camacho ME, Carrion MD, Lopez-Cara LC, Entrena A, Gallo MA, Espinosa A, Escames G, Acuna-Castroviejo D (2012) Melatonin synthetic analogs as nitric oxide synthase inhibitors. Mini-Rev Med Chem 12:600-617
124. Van Dijk KD, Teunissen CE, Drukarch B, Jimenez CR, Groenewegen HJ, Berendse HW, van de Berg WD (2010) Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol Dis 39:229-241
125. Antony PM, Diederich NJ, Balling R (2011) Parkinson's disease mouse models in translational research. Mamm Genome 22:401-419
126. Potashkin JA, Blume SR, Runkle NK (2010) Limitations of animal models of Parkinson's disease. Park Dis 2011:658083
127. Luo Z, Zhao Y, Wang Y, Yang X, Zhao B (2012) Protective effect of theaflavins on neuron against 6-hydroxydopamine-induced apoptosis in SH-SY5Y cells. J Clin Biochem Nutr 50:133-138
128. Ojha RP, Rastogi M, Devi BP, Agrawal A, Dubey GP (2012) Neuroprotective effect of curcuminoids against inflammation-mediated dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Neuroimmune Pharmacol 7:609-618
129. Kilbourn RG, Szabó C, Traber DL (1997) Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: lessons learned from experimental and clinical studies. Shock 7:235-246